Anna Rose Welch

Anna Rose Welch



Anna R. Welch is the executive editor for Biosimilar Development.com. She writes features on the latest news, issues, and trends in the biosimilar industry.

ARTICLES BY ANNA ROSE WELCH

  • Biosimilar Makers To Congress: Time To Act On REMS Legislation
    Biosimilar Makers To Congress: Time To Act On REMS Legislation

    REMS and voluntary restricted distribution programs have become a significant stumbling block for biosimilar companies. The Subcommittee on Health Care, Benefits, and Administrative Rules recently held a hearing on these controversial practices. If there was one big takeaway from the presenting witnesses, it’s that the biosimilars industry is ready for legislative action against these abuses.

  • The 4 Most Notable Biosimilar Interchangeability Hurdles
    The 4 Most Notable Biosimilar Interchangeability Hurdles

    Though the interchangeability draft guidance seemed to be well-received by biosimilar makers, I’m hesitant to interpret the surprising post-guidance quietness to mean companies have no concerns about the bar it sets for attaining interchangeability.

  • IQPC Biosimilars Event Emphasizes Need For Regulatory Alignment
    IQPC Biosimilars Event Emphasizes Need For Regulatory Alignment

    I recently attended the IQPC Biosimilars Analytical Similarity, Clinical Studies, and Market Entry conference. This event, which took attendees into the heart of biosimilar development (the analytical and statistical work) was a great example of the scientific challenges developers may face while working with different regulatory agencies.

  • Should Your Biosimilar Really Be A Biobetter?
    Should Your Biosimilar Really Be A Biobetter?

    A few months ago, Eagle Pharmaceuticals agreed to acquire Arsia Therapeutics.This move will help Eagle partner with biosimilar companies to turn biosimilar candidates into biobetters. As Eagle CEO Scott Tarriff describes, the company’s business model of reformulating and improving existing small molecules is well-suited to the biologics space — especially considering his expectations of how the biosimilar space will play out.

  • Celltrion: Data Transparency Imperative For Biosimilar Success
    Celltrion: Data Transparency Imperative For Biosimilar Success

    Over the past year, the biosimilar industry has developed two mantras: “education, education, education,” and “strategy, strategy, strategy.” But after my conversation with HoUng Kim, the head of the strategy and operations division for Celltrion Healthcare, I’d like to add another mantra to this list: “data, data, data.”

  • Top 5 Biosimilar Developments Of 2016
    Top 5 Biosimilar Developments Of 2016

    In the spirit of this list-making season, I compiled what I thought were the five most important biosimilar-related triumphs in the past year. Many of these events were widely covered by the media and will play an influential role in how the biosimilar industry unfolds through 2017 and beyond.

  • Health Canada’s Unique Approach To Biosimilar Regulation
    Health Canada’s Unique Approach To Biosimilar Regulation

    Health Canada recently released its revised guidance document on biosimilar submission requirements. Though the revisions were primarily “clarifications,” not major policy changes, some of these amendments provide a glimpse into the more unique aspects of Canada’s relationship with biosimilars.

  • The Case For Moving The EMA To Ireland
    The Case For Moving The EMA To Ireland

    Relocating an organization as large as the EMA, which employs upwards of 1,000 people in London, will be no easy feat. As such, IDA Ireland, an agency that supports companies in Ireland and promotes foreign direct investments in the country, is working to compile information on why Ireland would be a good location for the EMA.

  • Congress Takes On Biosimilars
    Congress Takes On Biosimilars

    During an interview at a briefing held by The Atlantic and The Biosimilars Council, Senator Bill Cassidy of Louisiana presented some valuable insights into where he believes more work needs to be done to ensure biosimilars’ market success.

  • FDA Stresses Scientific Alignment, Not Harmonization For Global Biosimilars
    FDA Stresses Scientific Alignment, Not Harmonization For Global Biosimilars

    In most cases, the biosimilar guidelines put forth by all the major regulatory agencies are quite similar. But there are some differences that can challenge companies looking to have their biosimilars approved in these different countries. 

More From Anna Rose Welch